| abstract |
The present disclosure relates to nanobodies, such as defined by SEQ ID NOS: 1 – 54, which may be encoded by SEQ ID NOS: 55 – 110, and which are capable of specifically binding glycoprotein VI (GPVI), as well as uses thereof, which include therapeutic and/or imaging uses. |